This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

proofread

Researchers report on intrathoracic synovial sarcoma with BRAF V600E mutation

Case Report: Intrathoracic synovial sarcoma with BRAF V600E mutation
(A) Axial T2 MR shows a heterogeneous mass in the cardiophrenic space with evidence of anterior chest wall invasion and intercostal invasion. (B) Axial T2 MR shows 35 % of reduction in size of the mass in the cardiophrenic space. Credit: Oncotarget (2023). DOI: 10.18632/oncotarget.28475

A new case report titled "Intrathoracic synovial sarcoma with BRAF V600E mutation" has been published in Oncotarget.

Synovial sarcoma (SS) is a highly malignant mesenchymal that occurs mainly in adolescents and young adults. The treatment of SS is multimodal, involving surgery, radiotherapy and chemotherapy. The overall prognosis is generally quite satisfactory in children and adolescents with localized SS at diagnosis. However, the outcome remains poor for patients who relapse, with a reported 5-year post-relapse survival of around 30%.

In this new paper, researchers Ida Russo, Sabina Barresi, Pier Luigi Di Paolo, Valentina Di Ruscio, Giada Del Baldo, Annalisa Serra, Silvia Vallese, Evelina Miele, Angela Mastronuzzi, Rita Alaggio, Andrea Ferrari, and Giuseppe Maria Milano from Italy's Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) report the case of a 15-year-old boy with intrathoracic synovial sarcoma who relapsed after standard chemotherapy, surgery and radiotherapy. The molecular analysis of the tumor identified a BRAF V600E mutation at time of progression of relapsed disease under third-line systemic treatment.

This mutation is commonly seen in and papillary thyroid cancers, but less prevalent (typically less than 5%) across a variety of other cancer types. The patient underwent selective BRAF inhibitor vemurafenib treatment achieving partial response (PR) with a progression-free survival (PFS) ratio of 1.6 months and an overall survival of 19 months, alive in continuous PR. This case highlights the role of routine next-generation sequencing (NGS) used to drive treatment choice and to investigate SS tumors for BRAF .

"Our data highlight the importance of implementing molecular tests in SS patients to evaluate BRAF mutational actual incidence in these neoplasms," the researchers conclude.

More information: Ida Russo et al, Intrathoracic synovial sarcoma with BRAF V600E mutation, Oncotarget (2023). DOI: 10.18632/oncotarget.28475

Journal information: Oncotarget

Provided by Impact Journals LLC
Citation: Researchers report on intrathoracic synovial sarcoma with BRAF V600E mutation (2023, July 18) retrieved 10 December 2023 from https://medicalxpress.com/news/2023-07-intrathoracic-synovial-sarcoma-braf-v600e.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Rare brain tumor responds to targeted tumor treatment with 'unprecedented' success

33 shares

Feedback to editors